20
Participants
Start Date
August 12, 2025
Primary Completion Date
August 12, 2028
Study Completion Date
August 12, 2028
Tb-PSMA-I&T (Tb-PSMA)
Terbium-161 produce beta emission with the addition of Auger electrons which have higher linear energy transfer and a very short range. By that it has the potential to improve local and distal (micro-metastatic disease) efficacy with a similar safety profile. It will be given to patients with high risk locally advanced prostate cancer prior to Radical prostatectomy
RECRUITING
Beilinson Hospital, Petah Tikva
Rabin Medical Center
OTHER